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The objective of this research is to develop a prototype Clinical Decision Support System (CDSS) to aid pathologists 
in correctly discriminating between reactive mesothelial cells and malignant epithelial cells. Currently, there is great 
difficulty in visually discriminating between cells that are malignant and cells that are otherwise reactive to antigens 
present in the effusion.  Features have been identified, which can correctly discriminate between benign epithelial 
cells and malignant epithelial cells with a validation AZ accuracy of ~ 0.934, training AZ of  ~ 0.937.   Using these 
features, the system trained on visually known cases was shown to find discriminating information in the feature 
subset of the atypical cases by examining probabilities generated from subjecting the system to atypical cells. While 
these results are preliminary, they do demonstrate that an intelligent CDSS, which has the potential to discriminate 
between reactive mesothelial cells and malignant epithelial cells, designed using newly developed and /or revised 
statistical learning theory (SLT) algorithms, has the potential to be used as a second opinion diagnostic aid by 
physicians, as they deem appropriate. 
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1. INTRODUCTION 
 
The primary objective of this paper is to describe the operational results for a recently developed CDSS for the 
classification of atypical cells in pleural effusion. It also has a second objective to provide some background and 
causes of pleural effusion for the reader unfamiliar with this medical condition.  
The two layer membrane consisting of mesothelial cells that lines the serous cavity of the lungs is called the 
Pleura. In some cases, this thin layer of cells undergoes a ‘reactive’ hypertrophy (enlargement) which causes the 
cells to swell up to a cubical (cuboidal) appearance. These cells are referred to as Reactive mesothelial cells 
(synonyms: Activated mesothelial cells, irritated mesothelial cells, hypertrophic or proliferative mesothelial cells).  
Reactive mesothelial cells can be found when there is an infection or an inflammatory response present in a body 
cavity. This condition can be due to the presence of a bacterial, viral or fungal infection. It can also be the result of 
trauma or the presence of metastatic tumor. More often than not, these cells detach from the lining of the cavity and 
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introduce themselves into the pleural fluid. These reactive mesothelial cells resemble malignant epithelial cells in 
that they are almost identical in terms of morphological features. When a sample of pleural effusion is observed 
under a microscope, it is almost impossible to differentiate between these two types of cells visually. 
Under normal conditions, there are certain amounts of fluid present in the pleural cavity. This fluid serves as a 
lubricant between the two pleural layers, provides nutrients, removes wastes and reduces surface tension. Pleural 
Effusion occurs when there is an imbalance in the haemostatic mechanism in the system. This imbalance in the 
mechanism can be caused due to infections, haemorrhage, malignancies and other disorders.  
There are two types of Pleural Effusions- Transudative effusion is one that is a result of a systemic disorder that 
disrupts the balance of fluid production / fluid re-absorption. This effusion is usually pale yellow and clear. 
Exudative effusion is one that is a result of a problem with the membranes themselves [1]. It is produced by 
conditions that directly involve the membranes of the particular cavity like infections, inflammations and 
malignancies. This effusion is of abnormal color and usually bloody, turbid or cloudy. 
When pleural fluid is extracted from the body and analysed under a microscope, the atypical cells are 
observed in order to determine the origin of the effusion. The malignant cells can be differentiated easily from the 
normal benign cells. However, the Reactive Mesothelial Cells mentioned earlier have multiple characteristics in 
common with malignant cells. This is the problem that many pathologists face.  
While immunohistochemical tests are the preferred method to overcome this problem [2], in the case where 
there is insufficient cellular material, differentiating between the Reactive Mesothelial cells and Malignant Epithelial 
cells becomes much more difficult. Cytological examination is another approach which has been used to diagnose 
pleural effusions, but which has shown to have a wide range of accuracies, and should not be used without support 
[3]. When available, these methods add extra cost and time to the diagnostic process. When unavailable, diagnosing 
malignancy in pleural effusion becomes a serious clinical problem. Precedence exists supporting the use of 
computerized imagery for diagnosis in serous effusions [4]. 
This brings us to the primary purpose of this paper, which is the description and operation of a preliminary CDSS 
based on available clinical data collected in this study to aid the physician in the classification of these atypical 
effusion cells. Our CDSS has been developed, implemented and preliminarily tested. However, since the developed 










2. SYSTEM OVERVIEW AND DESCRIPTION 
Pleural effusion can house a wide variety of cells which might be benign or malignant in nature. In some cases, 
pathologists are able to visually differentiate between the two by viewing slides of specifically stained fluid under a 
light microscope. But, in some cases, certain benign mesothelial cells undergo a reaction to antigens which render 
them visually similar to malignant epithelial cells. In this case, it is almost impossible to differentiate them visually 
based on morphological cell features. Moreover, the existing immunochemistry methods are not always helpful and 
sometimes cannot be used because of lack of adequate cellular material. The generic CDSS depicted in Figure 1 
below consists of the pleural effusion data set, the image processing software, software to obtain the features, 
intelligent processing software, some modeling software and validation processing, and, finally, the output provided 
by this new CDSS.  
An image of the cells is presented to the imaging processing software after slide preparation of pleural effusion 
sample. Pleural effusion collects at the bottom of the lung and depicted as a white space on chest X-ray (Figure 2).  
 















Figure 1. Generic Description of CDSS              Figure 2. Chest X-ray of pleural effusion 
 
An example of a graphical interface (GUI) image that is processed by the system is depicted in Figure 3, which 
demonstrates the process of a clinician interacting with the CDSS without the use of typed command lines—a very 
useful clinical attribute. Here the operator is processing three cells denoted by [9, 2, 3]. Current GUI operational 
features are: (1) ability to view imported image; (2) ability to “swap” between viewing original and segmented 
images; (3) test entry field that enables the clinician to type cell number for which cells to be included / excluded 
from analysis; (4) “buttons,” that when activated, will process the analysis for  both including / excluding cells. 
 A number of other primary and secondary functions (which are currently depicted by “placeholder buttons”) will be 
completed at a future time (i.e. classify button, which will provide an AZ value along with  the status of the cell 
analysis, intelligent adaptive system train and validate function buttons, and so on). 
Figure 3. Graphical User Interface (GUI) of the CDSS showing segmented nuclei 
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3. DATA PROCESSING AND PRELIMINARY RESULTS  
   
Figure 4 depicts examples of cell types contained in the image for this preliminary data set, which were collected 
and provided by Dr. Jagmohan Sidhu. This data set contained benign, malignant and atypical cases (which can be 
either benign or malignant). These atypical cells cannot be differentiated by visual means or by using 
immunochemistry because of the lack of adequate cellular material.  At the time of this writing, our data set is 























Figure 4: The system was preliminarily tested using a data set size of 928 segmented and usable nuclei.  
 
The intelligent processing systems for both the normal and  atypical benign / malignant data set were  trained and 
validated by an Evolutionary Programming /Evolutionary Strategies (EP /ES) hybrid process using five–fold cross 
validation.  The results are depicted in Table 1 below. 
 
Table 1. Performance for Five Trials of 5-fold Cross Validation 
Evaluation type AZ values for 5 trials of 5-fold cross validation  AVG SD 
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 
Training fold  0.933 0.936 0.940 0.939 0.938 0.937 0.003 
Validation fold  0.930 0.928 0.938 0.939 0.933 0.934 0.005 
 
Table 1 demonstrates that the EP /ES training of the intelligent processor provided training and validation accuracies 
for a clinically differentiable benign / malignant subset of the data set (a subset of data for which the pathologist can 
define benign and malignant epithelial cells) of 0.93 for both training and validation using a five-fold cross 
validation process using computer generated features.  
383 David Bassen et al. /  Procedia Computer Science  20 ( 2013 )  379 – 384 
 
Figure 5. Probabilities generated from the most and least confident 5-fold trials   
 
Figure 5 contains two histograms which are super imposed. To generate the intermediate grey histogram, 
probabilities were aggregated from all folds of the 5-fold run which classified the most cells in the high confidence 
range (83%). To generate the light grey histogram, probabilities were aggregated from all folds of the 5-fold run 
which classified the least cells in the high confidence range (70%). The two histograms are transparent such that 
darkest regions are overlapping regions of both histograms.  Since there are 202 atypical cells, there are 1010 
probabilities associated with each histogram. In total, 5050 probabilities were calculated for the five 5-fold runs.  
 
Figure 5 shows the confidence values (probabilities) of the CDSS system classifying atypical cases after being 
trained and validated on the visually known cases quantified in this study, where 0.0 represents a purely benign case 
and 1.0 a purely malignant case. While no ground truth currently exists to validate this operation in the same fashion 
as with visually identifiable cells, these results demonstrate that the patterns seen in the visually generated feature 
subset exist within the available atypical cell population. Note that a randomly trained system yields a uniform 
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Table 2. Confidence of PNN Configuration 1 in Classifying Atypical Cells 
Range Percentage of atypical cells in bin  AVG SD 
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 
High confidence 83% 81% 70% 73% 77% 77% 5% 
Low confidence  12% 14% 20% 18% 15% 16% 3% 
No confidence  6% 5% 10% 9% 7% 7% 2% 
Table 2. indicates the percentages of cells classified with 0.2 or lesser probability and 0.8 or greater probability, 
between 0.2 and 0.4 probability and between 0.6 and 0.8 probability, and between 0.6 and 0.7 probability. Each set 
of intervals defining confidence ranges of high, low, and no confidence, respectively. Note that for all 5050 
probabilities, 49.6% fall above 0.95 or below 0.05. 
 
    Table 2. provides a complete view of system confidence for all trials to support the point made by figure 5. In 
both depictions, the confidence of the system is measured as function of how well it generates two distinct peaks on 
the probability distribution. 
 
As a whole, this preliminary research has provided the following contributions: (1) generation of a quantified 
dataset derived from the nuclei of cells found in pleural effusion images; (2) an intelligent system capable of 
classifying visually known cases which was validated using ROC analysis (AZ around 0.90); (3) an intelligent 
system with the potential to classify atypical cells; (4) an assembled CDSS capable of accepting images from new 
cases and rendering output to a clinician. In doing so, this project has laid a framework for the quantitative use of 
pleural effusion images in the development of second opinion clinical decision support systems. 
Further progress will need to be made in conjunction with new data collection methods which allow a ground 






The purpose of this initial research effort is to develop a prototype CDSS to aid pathologists in correctly 
discriminating reactive benign mesothelial from malignant epithelial cells. Images of stained pleural effusion slides 
were collected by Dr. Jagmohan Sidhu. The project has provided:  (1) generation of a quantified dataset derived 
from the nuclei of cells found in pleural effusion images; (2) an intelligent system capable of classifying visually 
known cases which was validated using ROC analysis (AZ around 0.90); (3) an intelligent system with the potential 
to classify atypical cells; (4) an assembled CDSS capable of accepting images from new cases and rendering output 
to a clinician. In doing so, this project has laid a framework for the quantitative use of pleural effusion images in the 
development of second opinion clinical decision support systems. 
 Internal recommendations have been provided to guide future work with the intention of further validating the 
clinical usefulness of the system, its theoretical underpinnings, as well as to increase the quality and proper use of 
current and future data. Clearly, more data accompanied by patient outcomes and other experimental information 
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